New research suggests a link between some weight loss drugs and potentially blinding eye diseases. That risk is especially high for older adults. A recent study found that older adults with diabetes ...

All 50 states, D.C., and four U.S. territories signed off on the multi-billion dollar settlement proposal with OxyContin ...

A new drug is helping families who’ve spent years locking up or hiding food as their children with Prader-Willi syndrome deal ...

FAMILY doctors are pleading with patients to stop asking for fat jabs as they prepare to start a Mounjaro national rollout. NHS GPs will be able to prescribe the tirzepatide drug for weight loss ...

BARCELONA -- A rheumatology trainee who went on TikTok to find information on her own condition may have uncovered a novel ...

Wondering how to feel about Ozempic? These unexpected questions help reveal what may really be driving your reaction and how ...

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...

McDonald’s faces falling visits and shrinking demand as GLP-1 drugs and price fatigue reshape consumer habits.

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its 2025-26 budget plans.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.